GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer. (REVEAL)

Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer Treated With Total Neoadjuvant Therapy Followed by Watch and Wait or Total Mesorectal Excision Based on Clinical Assessment of Response

The evaluation of the tumor response to chemoradiotherapy/total neoadjuvant therapy (CRT/TNT) remains a challenge. The integration of a blood-based biomarker such as ctDNA with clinico-radiological tools could offer the potential advantage of improving accuracy of assessment of tumor response to neoadjuvant therapy. Furthermore, data on functional outcomes and quality of life after total mesorectal excision (TME) and especially after " Watch And Wait" (WW) is scarce.

REVEAL is a prospective, multicenter study in which the response to TNT in correlation with liquid biopsy (LB) of patients with rectal cancer in Spain will be evaluated. It is planned to include 120 patients. All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards. Patients will be included consecutively when visiting the corresponding health centers for outpatient visits or hospitalization.

The objective of the present study is to evaluate the role of ctDNA in the prediction of relapse in patients diagnosed with locally advanced rectal cancer (LARC) treated with TNT followed by WW or TME based on a clinical assessment of the local response

Study Overview

• Status: Active, not recruiting
• Conditions: Patients With Locally Advanced Rectal Cancer
• Intervention / Treatment: Drug: total neoadjuvant therapy

Detailed Description

The evaluation of the tumor response to chemoradiotherapy/total neoadjuvant therapy (CRT/TNT) remains a challenge. The integration of a blood-based biomarker such as ctDNA with clinico-radiological tools could offer the potential advantage of improving accuracy of assessment of tumor response to neoadjuvant therapy. Furthermore, data on functional outcomes and quality of life after total mesorectal excision (TME) and especially after " Watch And Wait" (WW) is scarce.

REVEAL is a prospective, multicenter study in which the response to TNT in correlation with liquid biopsy (LB) of patients with rectal cancer in Spain will be evaluated. It is planned to include 120 patients. All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards. Patients will be included consecutively when visiting the corresponding health centers for outpatient visits or hospitalization.

The objective of the present study is to evaluate the role of ctDNA in the prediction of relapse in patients diagnosed with locally advanced rectal cancer (LARC) treated with TNT followed by WW or TME based on a clinical assessment of the local response.

HYPOTHESIS ctDNA is a predictor of complete clinical response and could potentially be used to guide patient selection for WW strategy.

ctDNA is an early marker of local tumor relapse and could potentially guide strategy changes during follow-up.

Patients who are enrolled in a WW strategy have better long-term functional outcomes in comparison to patients who undergo surgery.

OBJECTIVES

PRIMARY:

To estimate the positive predictive value (PPV) and the negative predictive value (NPV) of the post-TNT ctDNA measurement to identify relapse (local or distant) in the 2 years after TNT.

SECONDARY:

Secondary objectives related to ctDNA and tumor response to TNT:

• To estimate the concordance between the post-TNT ctDNA measurement and the clinical evaluation of response (endoscopy-biopsy, DRE and MRI) to TNT.
• To estimate the concordance between the ctDNA measured after TNT and the endoscopy-biopsy evaluation of response.
• To estimate the concordance between the ctDNA measured after TNT and the MRI-defined response pattern groups.

Secondary objectives related to ctDNA measure during follow-up and relapse:

• To estimate the positive predictive value and the negative predictive value of ctDNA measured during the follow-up after TNT to identify relapse (local or distant) in the 2 years after TNT.
• To estimate the positive predictive value and the negative predictive value of ctDNA measured during the follow-up after TNT to identify local relapse in the 2 years after TNT
• To estimate the positive predictive value and the negative predictive value of ctDNA measured during the follow-up after TNT to identify distant relapse in the 2 years after TNT

Secondary objective related to functional impact of TME and WW:

-To describe anorectal, urinary and sexual function in the TME and WW groups.

Secondary objective related to ctDNA and survival:

-To assess the association of ctDNA levels (at baseline, post-treatment and during follow-up) with the survival outcomes (overall and disease-free survival, locoregional and distant recurrence, together with the pattern of recurrence).

• Study Type: Observational
• Enrollment (Estimated): 120

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain
    • H. de La Santa Creu I Sant Pau
  • Barcelona, Spain
    • H.U. Vall d'Hebron
  • Barcelona, Spain
    • Hospital Clínic, Universitat de Barcelona
  • Barcelona, Spain
    • Hospital del Mar, Barcelona
  • Barcelona, Spain
    • Hospital Sant Joan Despí - Moisés Broggi.
  • Barcelona, Spain
    • ICO-Hospitalet
  • Girona, Spain
    • ICO Girona
  • Madrid, Spain
    • H. Univeristario La Paz
  • Valencia, Spain
    • Hospital Quirón Salud Valencia
  • Valencia, Spain
    • Hospital Universitari i Politecnic La Fe
  • Zaragoza, Spain
    • Hospital Universitario Miguel Servet
  • Zaragoza, Spain
    • Hospital Clínico Universitario Lozano Blesa
  • Barcelona
    • Badalona, Barcelona, Spain
      • Hospital Germans Trias i Pujol - ICO Badalona
    • Terrassa, Barcelona, Spain
      • Hospital Universitari Mutua de Terrassa
  • Comunidad Autónoma De Madrid
    • Madrid, Comunidad Autónoma De Madrid, Spain, 28041
      • Hospital Universitario 12 de octubre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients diagnosed with locally advanced rectal cancer candidates to TNT. All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible.

All enrolled patients will be allocated to receive TNT according to standard clinical practice.

Description

Inclusion Criteria:

• Legally capable patients ≥ 18 years of age.
• Histologically confirmed rectal adenocarcinoma.
• Any tumor located in the mid or distal rectum, clinically staged II-III (cT3/4 and/or any TN+).
• Willingness to be enrolled in the WW strategy if cCR or nCCR is achieved.
• Absence of metastases on imaging.
• Scheduled to undergo TNT followed by delayed surgery.
• Patients who have signed the informed consent for this study.

Note: Decision was taken to treat the patient with a specific treatment prior and independently of patient inclusion in this non interventional study.

Exclusion Criteria:

• Patients who do not meet inclusion criteria.
• Concomitant colorectal tumors.
• Intolerance or contraindication to planned TNT.
• Other concurrent malignant diseases. Pregnancy or breastfeeding.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ctDNA from liquid biopsy	The results from ctDNA will be dichotomized to positive or negative. The investigator will report the percentage of patients with positive or negative ctDNA. Correlation of these values with clinical endpoints of response / survival to total neoadjuvant therapy will be done to fulfill the proposed objectives of this study. The ctDNA isolation test selected for this study is marketed by Guardant Health (Redwood City, California, USA) under the name Guardant RevealTM. It consists of a single state-of-the-art liquid blood biopsy, which is capable of detecting residual or recurrent disease seven days after blood extraction. This test uses a sequencing method that simultaneously evaluates genetic alterations and methylation without the need for a biopsy of the primary tumor tissue to determine specific mutations.	2 years after to start treatment total neoadjuvant therapy/2 years per patient

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response to TNT (cCR,nCCR)	Number of patients will be classified as responders (cCR, nCCR) or non responders based on the International Consensus Recommendations for Organ Preservation in Rectal Cancer. The number and percentage of each category will be reported. cCR: clinical complete response nCCR: near-complete clinical response	Throughout the study period, approximately 2 years per patient
Response to TNT (WW or TME)	The number and percentage of patients allocated to "watch and wait" (WW) or Total Mesorectal Excision (TMT) will be provided. Response rates will be also provided separately depending on the technique empowered to determine the response: Endoscopy-biopsy; MRI	Throughout the study period, approximately 2 years per patient
Locoregional failure rate (LRF)	Locoregional failure rate (LRF) defined as the percentage of patients who present progression(only for patients with nCCR)/relapse of disease in the rectum, regional organs and/or regional lymph nodes. Locoregional failure rate will be estimated using the appropriate logistic regression model at 1-year after the first dose of TNT and end of study. Those patients lost to follow-up with no event of local recurrence will be considered not evaluable for LFR endpoint. Patients who die as a direct or secondary cause of the cancer will be considered as an event at the date of death for LFR analysis. Death by other reasons other than cancer progression/relapse will not be considered as an event for LFR.	Throughout the study period, approximately 2 years per patient
Distant relapse rate (DRR)	Distant relapse rate (DRR) defined as the percentage of patients who present progression/relapse of disease in distant locations. DRR will be estimated using the appropriate logistic regression model at 1-year after the first dose of TNT and end of study. Those patients lost to follow-up with no event of distal recurrence will be considered not evaluable for DRR endpoint. Patients who die as a direct or secondary cause of the cancer will be considered as an event at the date of death for DRR analysis. Death by other reasons other than cancer progression/relapse will not be considered as an event for DRR.	Throughout the study period, approximately 2 years per patient
Disease-free Survival (DFS)	Disease-free Survival (DFS): defined as the time elapsed from the first dose of TNT to progression (only for pts with nCCR), relapse, or death from any cause, whichever occurs first. The investigators will assess the median DFS, the DFS rate at 1 year, and at the end of study. The 1-year DFS rate is defined as the rate of patients alive and free of relapse or progression at 1 year after the first dose of TNT estimated by Kaplan-Meier. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment.	at 1 year after the first dose of TNT and at the end of study (approximately 2 years)
Disease-specific Survival (DSS)	Disease-specific Survival (DSS): defined as the time elapsed from the first dose of TNT to the date of progression(only for pts with nCCR), relapse, or death due to the disease, whichever occurs first. We will assess the median DSS, the DSS rate at 1 year, and at the end of study. The 1-year DSS rate is defined as the rate of patients alive and free of event at 1 year after the first dose of TNT, estimated by Kaplan-Meier. Patients alive and free of events at the date of the analysis will be censored at their last known contact.	at 1 year after the first dose of TNT
Overall Survival (OS)	Overall Survival (OS) : defined as the time elapsed from the first dose of TNT until death from any cause. We will assess the median OS and the OS rate at 1 year. The 1-year OS rate is defined as the rate of patients alive at 1 year after the first dose of TNT, estimated by Kaplan-Meier. Patients alive and free of events at the date of the analysis will be censored at their last known contact.	at 1 year after the first dose of TNT
Mortality	Mortality: Rate of patients who died during the study. The number and percentage of patients will be provided.	Throughout the study period, approximately 2 years per patient
TNT compliance	TNT compliance: total number of dose reductions and modifications of the treatment throughout the study period.	Throughout the study period, approximately 2 years per patient

Collaborators and Investigators

• Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
• Investigators: Study Chair: Joan Maurel Santasusana, M.D., Ph.D., Servicio de Oncología, Hospital Clínic, Universitat de Barcelona; Study Chair: Juan Ramón Ayuso, M.D., Ph.D., Servicio de Radiología, Hospital Clínic, Universitat de Barcelona; Study Chair: Yoelimar Guzmán, M.D., Servicio de Cirugía General y Digestiva, Hospital Clínic, Universitat de Barcelona

Study record dates

Study Major Dates

• Study Start (Actual): May 26, 2023
• Primary Completion (Estimated): April 26, 2025
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: December 30, 2022
• First Submitted That Met QC Criteria: December 30, 2022
• First Posted (Actual): January 6, 2023

Study Record Updates

• Last Update Posted (Actual): October 31, 2024
• Last Update Submitted That Met QC Criteria: October 29, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: rectal cancer; ctDNA; total neoadjuvant therapy
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colorectal Neoplasms; Intestinal Neoplasms; Rectal Diseases; Rectal Neoplasms
• Other Study ID Numbers: GEMCAD 2201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No